Natixis Advisors
KYMR icon

Natixis Advisors’s Kymera Therapeutics KYMR Stock Holding History

Natixis Advisors’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-14,334
Closed -$392K – 1657
2025
Q1 		$392K Buy
14,334
+262
+2% +$9.55K ﹤0.01% 1507
2024
Q4 		$566K Sell
14,072
-306
-2% -$13.8K ﹤0.01% 1446
2024
Q3 		$681K Buy
+14,378
New +$635K ﹤0.01% 1395

Other funds holding KYMR

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Natixis Advisors's KYMR Position: Q2 2025 in Review

Natixis Advisors sold out of Kymera Therapeutics (KYMR) in Q2 2025, closing a stake of 14,334 shares — an estimated $392K sold.

Natixis Advisors first reported a position in KYMR in Q3 2024 and held it in 3 quarters. The position peaked at $681K in Q3 2024. 210 funds tracked by Wall St. Rank hold KYMR as of Q2 2025.

  • Natixis Advisors reported no remaining Kymera Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Natixis Advisors sold 14,334 Kymera Therapeutics shares in Q2 2025, an estimated $392K.
  • Natixis Advisors first reported a position in Kymera Therapeutics in Q3 2024 and held it in 3 quarters.
  • Natixis Advisors's Kymera Therapeutics position peaked at $681K in Q3 2024.
  • 210 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2025.

Based on Natixis Advisors's 13F filing for Q2 2025, filed 13 Aug 2025.